Biocon Phase III data on switching biosimilar aflibercept

24 October 2024

Indian drugmaker Biocon (BSE: 532523) subsidiary Biocon Biologicals has released a new extension study evaluating MYL-1701P, a proposed biosimilar to ophthalmic drug aflibercept, which is marketed by Germany’s Bayer (BAYN: DE) under the trade name Eylea.

Regeneron (Nasdaq: REGN), which developed aflibercept and licensed it to Bayer, has been in legal battles with other companies developing biosimilars, including Sandoz (SWX: SDZ) and Samsung Bioepis. Regeneron has had some success in court in recent months, with a judge in West Virginia granting a permanent injunction preventing Biocon Biologics from marketing its Eylea biosimilar, Yesafili (aflibercept-jbvf).

MYL-1701P showed promising results, demonstrating comparable safety, efficacy, and immunogenicity between patients continuing on MYL-1701P and those who switched from aflibercept to MYL-1701P. The data were presented at the annual meeting of the American Academy of Ophthalmology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK